Unravel Biosciences Partners with TMA Precision Health to Advance Drug Treatment for Rett Syndrome into the Clinic
- Tuesday, July 5, 2022, 8:32
- Finance
- Add a comment
BOSTON, July 5, 2022 /PRNewswire/ — Unravel Biosciences, Inc. (“Unravel”), a therapeutics company that spun out from the Wyss Institute for Biologically Inspired Engineering at Harvard University, seamlessly bridges target discovery with clinical efficacy to advance drugs for complex…
About the Author
adminasapcorp has written 41546 stories on this site.